Immunohistochemistry versus PCR Technology for Molecular Subtyping of Breast Cancer: Multicentered Expereinces from Addis Ababa, Ethiopia.
Breast cancer
Immunohistochemistry
Molecular subtypes
Reverse transcription polymerase chain reaction
Journal
Journal of cancer prevention
ISSN: 2288-3649
Titre abrégé: J Cancer Prev
Pays: Korea (South)
ID NLM: 101615965
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
28
01
2023
revised:
25
04
2023
accepted:
26
04
2023
medline:
12
7
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
ppublish
Résumé
The application of immunohistochemistry (IHC) for molecular characterization of breast cancer (BC) is of paramount importance; however, it is not universally standardized, subject to observer variability and quantifying is a challenge. An alternative molecular technology, such as endpoint reverse transcription (RT)-PCR gene expression analysis, may improve observer variability and diagnostic accuracy. This study was intended to compare IHC with the RT-PCR based technique and assess the potential of RT-PCR for molecular subtyping of BC. In this comparative cross-sectional study, 54 BC tissues were collected from three public hospitals in Addis Ababa and shipped to Gynaecology department at Martin-Luther University (Germany) for laboratory analysis. Only 41 samples were qualified for IHC and RT-PCR investigation of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki-67 protein expression analysis. Kappa statistics was used to assess the concordance between the two techniques. The overall percent agreement between RT-PCR and IHC was 68.3% for ER (positive percent agreement [PPA] 71.1%; negative percent agreement [NPA] 33.3%), 39.0% for PR (PPA 14.3%; NPA 92.3%), and 82.9% for HER2 (PPA 62.5%; NPA 87.9%). Cohen's κ-values of 0.018 (< 0.20), 0.045 (< 0.200), and 0.481 (0.41-0.60) were generated for ER, PR, and HER2, respectively. Concordance for molecular subtypes was only 56.1% (23/41) and 0.20 kappa value. IHC and endpoint RT-PCR techniques have shown to be discordant for 43% samples. Molecular subtyping using endpoint RT-PCR was fairly concordant with IHC. Thus, endpoint RT-PCR may give an objective result, and can be applied for BC subtyping.
Identifiants
pubmed: 37434799
doi: 10.15430/JCP.2023.28.2.64
pii: jcp-28-2-64
pmc: PMC10331035
doi:
Types de publication
Journal Article
Langues
eng
Pagination
64-74Informations de copyright
Copyright © 2023 Korean Society of Cancer Prevention.
Déclaration de conflit d'intérêts
CONFLICTS OF INTEREST No potential conflicts of interest were disclosed.
Références
Asian Pac J Cancer Prev. 2016;17(S3):43-6
pubmed: 27165206
Breast Cancer Res. 2021 Jun 26;23(1):68
pubmed: 34174935
Breast Cancer Res. 2014 Jun 20;16(3):R65
pubmed: 24951027
Nature. 2000 Aug 17;406(6797):747-52
pubmed: 10963602
Horm Cancer. 2020 Oct;11(5-6):240-249
pubmed: 32772262
Pan Afr Med J. 2019 May 14;33:22
pubmed: 31312338
BMC Med Genomics. 2012 Oct 04;5:44
pubmed: 23035882
PLoS One. 2017 Jan 3;12(1):e0168669
pubmed: 28045912
Breast Cancer Res Treat. 2018 Nov;172(2):327-338
pubmed: 30120700
BMC Cancer. 2021 Apr 21;21(1):439
pubmed: 33879115
Nat Commun. 2020 Apr 14;11(1):1787
pubmed: 32286297
Arch Pathol Lab Med. 2016 Sep;140(9):893-8
pubmed: 27575264
Breast Dis. 2015;35(2):95-102
pubmed: 25736840
Breast Cancer Res Treat. 2014 Apr;144(3):467-78
pubmed: 24604092
Front Oncol. 2020 Dec 14;10:604214
pubmed: 33409154
Ann Oncol. 2013 Sep;24(9):2206-23
pubmed: 23917950
J Cancer Epidemiol. 2012;2012:915610
pubmed: 22693503
BMC Cancer. 2016 Jul 07;16:398
pubmed: 27389414
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Front Pharmacol. 2021 Feb 26;11:632079
pubmed: 33716731
Cancer Epidemiol. 2018 Apr;53:93-98
pubmed: 29414637
Ecancermedicalscience. 2017 Aug 30;11:763
pubmed: 28900476
Arch Pathol Lab Med. 2010 Jul;134(7):e48-72
pubmed: 20586616
Arch Pathol Lab Med. 2014 Feb;138(2):241-56
pubmed: 24099077
BMC Cancer. 2014 Nov 29;14:895
pubmed: 25433805
Genome Biol. 2003;4(9):117
pubmed: 12952525
Pan Afr Med J. 2021 Jan 26;38:85
pubmed: 33889251
BMC Womens Health. 2018 Feb 14;18(1):40
pubmed: 29444670
Hum Pathol. 2008 Apr;39(4):506-13
pubmed: 18289638
ESMO Open. 2020 Oct;5(5):e000829
pubmed: 33020218
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
pubmed: 11553815
Diagn Mol Pathol. 2011 Mar;20(1):1-10
pubmed: 21326033
Sci Rep. 2014 Oct 23;4:6566
pubmed: 25338681
Ann Surg Oncol. 2016 Nov;23(12):3843-3849
pubmed: 27469125
BMC Cancer. 2017 Feb 13;17(1):124
pubmed: 28193205
BMC Womens Health. 2020 Nov 23;20(1):261
pubmed: 33228656
Breast Cancer Res Treat. 2016 Jun;157(3):437-46
pubmed: 27220750
PLoS Med. 2012;9(3):e1001182
pubmed: 22412354